Wijziging van de Wet geneesmiddelenprijzen in verband met een aanpassing van de referentielanden

This procedure involves an amendment to the Dutch Medicine Prices Act. It focuses on updating the list of reference countries used to determine the maximum prices for pharmaceutical products in the Netherlands. This change primarily affects pharmaceutical companies and healthcare payers by adjusting how drug pricing benchmarks are calculated and applied.